아리벤트 바이오파마(AVBP)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $29.02 (+2.33%), 시가총액 $1.30B, 52주 최저~최고 $16.95 ~ $31.39.
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-hel
아리벤트 바이오파마의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
아리벤트 바이오파마의 현재 주가는 $29.02 (+2.33%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
아리벤트 바이오파마의 시가총액은 약 $1.30B입니다.
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancer